Table 1 Haematological and non-haematological adverse events occurring in 20% of patients or reaching grade 4 severity

From: Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

Adverse event

Any grade, n =15 (%)

Grade 1 n (%)

Grade 2 n (%)

Grade 3 n (%)

Grade 4 n (%)

Haematological adverse events

 Neutropenia

13 (86)

2 (13)

3 (20)

8 (53)

 Anemia

11 (73)

3 (20)

6 (40)

2 (13)

 Leukopenia

11 (73)

3 (20)

5 (33)

3 (20)

 Lymphopenia

5 (33)

1 (7)

1 (7)

2 (13)

1 (7)

 Thrombocytopenia

2 (13)

1 (7)

1 (7)

 Neutropenic fever

2 (13)

2 (13)

Non-haematological adverse events

 Nausea

12 (80)

10 (67)

2 (13)

 Asthenia

10 (67)

6 (40)

3 (20)

1 (7)

 Pain

8 (53)

3 (20)

3 (20)

1 (7)

1 (7)

 Vomiting

8 (53)

4 (27)

3 (20)

1 (7)

 Chills

7 (47)

3 (20)

4 (27)

 Cough

5 (33)

4 (27)

1 (7)

 Fever

5 (33)

4 (27)

1 (7)

 Anorexia

5 (33)

3 (20)

1 (7)

1 (7)

 

 Alopecia

5 (33)

4 (27)

1 (7)

 Constipation

4 (27)

1 (7)

3 (20)

 Mucositis

4 (27)

2 (13)

2 (13)

 Insomnia

4 (27)

3 (20)

1 (7)

 GGTP increase

3 (20)

1 (7)

1 (7)

1 (7)

 

 Gastritis

3 (20)

1 (7)

2 (13)

 Headache

3 (20)

1 (7)

2 (13)

 Dysphagia

3 (20)

3 (20)

 AMI

1 (7)

1 (7)

 Pulmonary embolism

1 (7)

1 (7)

  1. Abbreviations: AMI, acute myocardial ischaemia; GGTP, gamma-glutamyl transferase.